Apatinib plus Docetaxel for Treating Taxol Resistant Patients with Ovarian Cancer
Latest Information Update: 13 Jun 2017
At a glance
- Drugs Docetaxel (Primary) ; Rivoceranib (Primary)
- Indications Ovarian cancer
- Focus Therapeutic Use
- 13 Jun 2017 New trial record